Emicizumab 105mg/0.7ml solution for injection vials
NHS hospitals in England used £127,555,616 of indicative cost of Emicizumab 105mg/0.7ml solution for injection vials in the 12 months to July 2026, about 0.5% of all hospital medicines spend. That is up 3.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Emicizumab 105mg/0.7ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Emicizumab 105mg/0.7ml solution for injection vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £20,964,804 |
| Manchester University Nhs Ft | £18,234,307 |
| Royal Free London Nhs Foundation Trust | £11,530,642 |
| Sheffield Teaching Hospitals Nhs Trust | £10,135,806 |
| Leeds Teaching Hpls Nhs Trust | £10,051,271 |
| Univ Hpls Bristol Nhs Foundation Trust | £9,112,927 |
| Barts Health Nhs Trust | £8,140,769 |
| Nottingham University Hospitals Trust | £7,202,425 |
| Aintree University Hospital Nhs Ft | £5,097,491 |
| Oxford University Hospitals Nhs Ft | £4,919,966 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.